A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Imatinib (Primary) ; Paclitaxel (Primary)
- Indications Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Nov 2020 Biomarkers information updated
- 27 Sep 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 27 Sep 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.